Article

Countdown to a possible new drug approval for kidney cancer

Author(s):

Melissa Weber

Just got word from a Genentech spokesperson that the company expects to hear by the end of this week whether the FDA will approve Avastin for metastatic kidney cancer. (Check out the kidney cancer feature in our current issue.)We'll keep you posted.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content
Image of breast.
April 30th 2025

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

Ryan Scott
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Illustration of woman with blonde hair.
April 30th 2025

Lingering Stress After Follicular Lymphoma Remission is a Challenge

Karen Cohn
Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of brain.
April 30th 2025

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

Ryan Scott
Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
An illustration of blood cancer
April 30th 2025

SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

Spencer Feldman
A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.